News
Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.
French pharmaceuticals giant Sanofi has agreed to buy Blueprint Medicines Corp. for at least $9.1 billion as the company aims to expand the company's reach in rare immunological diseases, reported ...
Sanofi has agreed to acquire Blueprint Medicines for up to approximately $9.5 billion, in a deal designed to expand the buyer’s rare immunological disease portfolio with an FDA-approved ...
French pharmaceutical company Sanofi said on Tuesday it was exploring opportunities for producing vaccines in Vietnam in cooperation with local partner Vietnam Vaccine Company (VNVC), which ...
Sanofi spent $130 million outfitting the 260,000 square feet it now occupies for 2,000 employees at M Station West.
Sanofi relocated 2,000 employees to a new $130M Morristown flagship office at M Station West in May, leaving Bridgewater.
Sanofi has entered an agreement to acquire Vigil Neuroscience for approximately $470 million, adding a new investigational treatment for Alzheimer’s disease to the French pharmaceutical company ...
Morristown-based Sanofi will be the latest U.S. drugmaker to inject billions of dollars into domestic operations and American manufacturing.
Sanofi said it will invest at least $20 billion in the US through 2030, joining other pharmaceutical companies boosting their American operations as President Donald Trump threatens to impose ...
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states.
In a report released today, Emily Field from Barclays maintained a Buy rating on Sanofi (SNYNF – Research Report), with a price target of €125.0 ...
Discover whether AbbVie or Sanofi holds the edge in the global immunology market and find out which stock shows more long-term promise.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results